cite
articl
keller
tt
van
wissen
mairuhu
ata
van
doornum
gjj
brandj
dpm
acut
respiratori
tract
infect
elderli
patient
increas
system
level
hemostat
protein
j
thromb
haemost
acut
respiratori
tract
infect
associ
temporarili
increas
risk
acut
ischem
heart
diseas
venou
thrombosi
precis
underli
mechan
associ
unclear
infectioninduc
system
inflamm
transient
coagul
activ
endotheli
cell
perturb
may
contribut
endotheli
cell
perturb
coagul
activ
associ
increas
risk
futur
ischem
heart
diseas
sever
crosssect
report
show
increas
level
hemostat
protein
symptom
acut
respiratori
tract
infect
howev
find
difficult
interpret
diagnosi
unequivoc
establish
whether
virus
infect
respiratori
tract
inde
perturb
endotheli
cell
therebi
increas
risk
acut
ischem
heart
diseas
remain
proven
therefor
determin
effect
natur
occur
acut
respiratori
tract
infect
hemostat
protein
prospect
studi
includ
differ
subject
gener
practis
mean
age
year
year
elig
subject
risk
influenza
defin
criteria
particip
nation
influenza
vaccin
campaign
institut
review
board
approv
studi
subject
provid
inform
consent
time
inclus
medic
histori
includ
influenza
vaccin
statu
obtain
blood
sampl
collect
immedi
thereaft
followup
period
start
blood
sampl
nose
swab
obtain
predefin
criteria
flulik
symptom
met
defin
flulik
diseas
acut
onset
fever
bodi
temperatur
plu
least
two
follow
flulik
symptom
headach
myalgia
sore
throat
cough
specimen
obtain
first
day
flulik
symptom
convalesc
phase
day
begin
symptom
specimen
collect
repeat
blood
collect
empti
vacuum
tube
tube
contain
trisodium
citrat
sampl
taken
morn
process
within
min
tube
centrifug
min
g
plasma
pool
centrifug
g
min
subsequ
plasma
frozen
store
aliquot
ml
prothrombin
fragment
f
plasmina
antiplasmin
pap
complex
measur
enzymelink
immunosorb
assay
elisa
dade
behr
marburg
germani
plasminogen
activ
inhibitor
type
antigen
measur
elisa
hyphen
biom
franc
von
willebrand
factor
vwf
antigen
measur
elisa
dako
glostrup
denmark
result
vwf
present
percentag
normal
pool
plasma
presenc
antibodi
respiratori
pathogen
establish
use
elisa
influenza
viru
influenza
b
viru
parainfluenza
viru
type
type
respiratori
syncyti
viru
rsv
adenoviru
specif
igm
igg
mycoplasma
pneumonia
detect
iga
antibodi
inhous
assay
use
detect
igg
igm
antibodi
test
purchas
serionviron
germani
use
consid
respiratori
tract
infect
proven
elev
sampl
taken
first
day
flulik
symptom
sampl
taken
convalesc
phase
week
later
addit
sampl
test
rsv
influenza
virus
type
type
b
parainfluenza
virus
adenoviru
enteroviru
rhinoviru
human
metapneumoviru
hmpv
routin
diagnost
immunofluoresc
assay
h
inocul
total
rna
dna
isol
total
nucleic
acid
isol
kit
roch
appli
scienc
almer
netherland
amplif
hmpv
human
coronaviru
influenza
viru
perform
describ
previous
amplif
rsv
type
type
b
rhinoviru
coronaviru
coronaviru
perform
use
taqman
ez
rtpcr
reagent
appli
biosystem
nieuwerkerk
ad
ijssel
netherland
detect
perform
detect
system
materi
spike
intern
control
consist
fix
amount
phocin
distemp
viru
monitor
inhibit
andor
loss
materi
data
present
median
interquartil
rang
iqr
level
hemostat
protein
baselin
acut
phase
diseas
baselin
convalesc
phase
compar
use
wilcoxon
rank
sum
test
pvalu
consid
statist
signific
winter
total
subject
report
flulik
symptom
met
predefin
criteria
flulik
diseas
subject
flulik
diseas
show
increas
vwf
level
tabl
median
vwf
level
chang
iqr
baselin
iqr
start
symptom
p
thrombin
gener
increas
evidenc
compar
level
f
baselin
acut
phase
diseas
subject
flulik
diseas
fibrinolysi
activ
demonstr
increas
median
pap
level
lg
l
iqr
lg
l
iqr
p
level
chang
convalesc
phase
week
start
symptom
vwf
pap
level
return
baselin
caus
pathogen
includ
influenza
viru
influenza
b
viru
parainfluenza
viru
rsv
coronaviru
found
case
flulik
diseas
subject
proven
viral
infect
vwf
antigen
level
increas
iqr
infect
p
convalesc
phase
week
start
symptom
vwf
level
return
baselin
median
pap
level
increas
lg
l
iqr
howev
increas
pap
statist
signific
final
compar
level
hemostat
protein
subject
influenza
infect
proven
viral
infect
clinic
symptom
signific
differ
found
vwf
f
pap
level
subgroup
studi
demonstr
acut
respiratori
tract
infect
result
increas
hemostat
protein
vwf
pap
vascular
point
impact
seem
endothelium
evidenc
increas
vwf
studi
first
prospect
show
hemostat
protein
increas
patient
proven
acut
respiratori
tract
infect
although
other
report
similar
chang
patient
flulik
symptom
crosssect
natur
studi
prohibit
definit
conclus
whether
acut
respiratori
tract
infect
fact
caus
chang
studi
limit
selfreport
clinic
symptom
use
establish
diagnosi
infect
may
confound
result
noninfecti
inflammatori
diseas
may
also
present
fever
combin
cough
prospect
natur
studi
render
effect
season
variat
marker
coagul
fibrinolysi
quit
unlik
although
hemostat
protein
minim
season
variat
fact
level
hemostat
protein
return
normal
convalesc
phase
week
initi
diseas
episod
negat
option
observ
increas
result
variat
also
baselin
measur
winter
season
abl
exclud
possibl
increas
level
hemostat
protein
result
preexist
condit
result
obtain
conclud
natur
occur
respiratori
tract
infect
elderli
human
subject
result
endotheli
cell
perturb
potenti
associ
dysfunct
hemostat
chang
may
form
link
acut
respiratori
tract
infect
acut
atherothrombot
diseas
howev
precis
increment
risk
still
need
establish
prospect
studi
data
present
median
interquartil
rang
level
hemostat
protein
measur
baselin
acut
convalesc
phase
diseas
significantli
differ
p
baselin
calcul
wilcoxon
rank
sum
test
statist
signific
differ
convalesc
phase
infect
baselin
observ
